Calmus Y - Search Results

1

Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.

Aoudjehane L, Boelle PY, Bisch G, Delelo R, Paye F, Scatton O, Housset C, Becquart J, Calmus Y, Conti F. Aoudjehane L, et al. Among authors: calmus y. Lab Invest. 2016 Jun;96(6):672-9. doi: 10.1038/labinvest.2016.36. Epub 2016 Mar 7. Lab Invest. 2016. PMID: 26950484 Free article.

2

Infection of Human Liver Myofibroblasts by Hepatitis C Virus: A Direct Mechanism of Liver Fibrosis in Hepatitis C.

Aoudjehane L, Bisch G, Scatton O, Granier C, Gaston J, Housset C, Roingeard P, Cosset FL, Perdigao F, Balladur P, Wakita T, Calmus Y, Conti F. Aoudjehane L, et al. Among authors: calmus y. PLoS One. 2015 Jul 27;10(7):e0134141. doi: 10.1371/journal.pone.0134141. eCollection 2015. PLoS One. 2015. PMID: 26214688 Free PMC article.

3

Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway.

Aoudjehane L, Pissaia A Jr, Scatton O, Podevin P, Massault PP, Chouzenoux S, Soubrane O, Calmus Y, Conti F. Aoudjehane L, et al. Among authors: calmus y. Lab Invest. 2008 Sep;88(9):973-85. doi: 10.1038/labinvest.2008.61. Epub 2008 Jul 14. Lab Invest. 2008. PMID: 18626468 Free article.

4

Is the liver a tolerogenic organ?

Calmus Y, Conti F. Calmus Y, et al. Clin Res Hepatol Gastroenterol. 2014 Dec;38(6):655-8. doi: 10.1016/j.clinre.2014.08.009. Epub 2014 Sep 26. Clin Res Hepatol Gastroenterol. 2014. PMID: 25260569 No abstract available.

5

Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis.

Aoudjehane L, Gautheron J, Le Goff W, Goumard C, Gilaizeau J, Nget CS, Savier E, Atif M, Lesnik P, Morichon R, Chrétien Y, Calmus Y, Scatton O, Housset C, Conti F. Aoudjehane L, et al. Among authors: calmus y. Dis Model Mech. 2020 Apr 29;13(4):dmm042663. doi: 10.1242/dmm.042663. Dis Model Mech. 2020. PMID: 32094147 Free PMC article.

6

Domino liver transplantation: the risk of disease recurrence.

Conti F, Mochel F, Calmus Y. Conti F, et al. Among authors: calmus y. Clin Res Hepatol Gastroenterol. 2019 Oct;43(5):510-512. doi: 10.1016/j.clinre.2019.01.004. Epub 2019 Feb 14. Clin Res Hepatol Gastroenterol. 2019. PMID: 30773354 No abstract available.

7

[No title available]

[No authors listed] [No authors listed] PMID: 34005068

8

Liver transplantation using grafts with rare metabolic disorders.

Schielke A, Conti F, Goumard C, Perdigao F, Calmus Y, Scatton O. Schielke A, et al. Among authors: calmus y. Dig Liver Dis. 2015 Apr;47(4):261-70. doi: 10.1016/j.dld.2014.11.004. Epub 2014 Nov 13. Dig Liver Dis. 2015. PMID: 25498135 Free article. Review.

9

Immunosuppressive therapy in liver transplantation.

Conti F, Morelon E, Calmus Y. Conti F, et al. Among authors: calmus y. J Hepatol. 2003 Nov;39(5):664-78. doi: 10.1016/s0168-8278(03)00428-8. J Hepatol. 2003. PMID: 14568246 Review. No abstract available.

10

CD28 expression by peripheral blood lymphocytes as a potential predictor of the development of de novo malignancies in long-term survivors after liver transplantation.

Boleslawski E, Othman SB, Aoudjehane L, Chouzenoux S, Scatton O, Soubrane O, Calmus Y, Delhem N, Conti F. Boleslawski E, et al. Among authors: calmus y. Liver Transpl. 2011 Mar;17(3):299-305. doi: 10.1002/lt.22232. Liver Transpl. 2011. PMID: 21384512 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page